MET and cancer: Among these agents, Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive, small-molecule inhibitor of c-MET and anaplastic lymphoma kinase, and is considered a very potential agent for treatment of cancers dependent on these oncogenic kinases for growth and survival [35,36].